Sex differences in the metabolism of (+)-S-145, a novel thromboxane A(2) receptor antagonist in rat

被引:4
|
作者
Yamaguchi, Y
Norikura, R
Nakanishi, M
Touchi, A
Yoshimori, T
Murakami, T
Baba, T
Mizojiri, K
Matsubara, T
机构
[1] Dept. of Drug Metab. and Disposition, Developmental Research Laboratories, Shionogi and Co., Ltd., Toyonaka
关键词
D O I
10.3109/00498259609046737
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1. After the oral administration of 5 mg/kg 5-1452 to rat, the plasma levels of (+)-S-145 were similar between the male and female, but there were sex differences in the profiles of its beta-oxidized and hydroxylated metabolites in plasma. 2. beta-Oxidation of(+)-S-145 determined in vitro was slightly higher in the female than in the male, and agreed with the plasma levels of the beta-oxidized metabolites. 3. 5-Hydroxylation activities of (+)-S-145 and beta-oxidized metabolites by rat liver microsomes were significantly higher in the male than in the female, but marked sex differences were not observed in 6-hydroxylation activities. These results revealed that differences in monooxygenase activities directly account for the sex differences in the plasma level of 5-hydroxylated metabolites, and that the peroxisomal beta-oxidation enzyme system also affected the plasma level of 6-hydroxylated metabolites. 4. Biliary excretion was higher in the male than in the female, and quantitative identification of metabolites in bile indicated that this was based on the prominent excretion of taurine conjugates in the male rat. This conclusion was supported by the fact that taurine conjugation activity was higher in male liver homogenates than in the female.
引用
收藏
页码:613 / 626
页数:14
相关论文
共 50 条
  • [31] OXO-HT IS A NOVEL ENDOGENOUS THROMBOXANE-A(2) RECEPTOR ANTAGONIST
    RUF, A
    MUNDKOWSKI, R
    HOFMANN, U
    PATSCHEKE, H
    MEESE, CO
    THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) : 915 - 915
  • [32] Seratrodast (AA-2414) - A novel thromboxane-A(2) receptor antagonist
    Samara, EE
    CARDIOVASCULAR DRUG REVIEWS, 1996, 14 (03): : 272 - 285
  • [33] CINNAMOPHILIN, A NOVEL THROMBOXANE A(2) RECEPTOR ANTAGONIST, ISOLATED FROM CINNAMOMUM PHILIPPINENSE
    YU, SM
    KO, FN
    WU, TS
    LEE, JY
    TENG, CM
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1994, 256 (01) : 85 - 91
  • [34] EFFECT OF A NOVEL THROMBOXANE-A(2) RECEPTOR ANTAGONIST, S-1452, ON POSTISCHEMIC BRAIN INJURY IN RATS
    MATSUO, Y
    IZUMIYAMA, M
    ONODERA, H
    KUROSAWA, A
    KOGURE, K
    STROKE, 1993, 24 (12) : 2059 - 2065
  • [35] PHARMACOKINETICS AND PHARMACODYNAMICS OF A THROMBOXANE A2 RECEPTOR ANTAGONIST
    FRIEDHOFF, LT
    FRY, J
    IVASHKIV, E
    JEMAL, M
    WILLARD, DA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 43 (02) : 139 - 139
  • [36] PROTECTIVE EFFECTS OF THE SPECIFIC THROMBOXANE RECEPTOR ANTAGONIST (+)-S145NA IN SPLANCHNIC ARTERY-OCCLUSION SHOCK IN RATS
    FURLAN, LE
    JOHNSON, G
    SIEGFRIED, M
    LEFER, AM
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1990, 253 (02): : 525 - 529
  • [37] CORRECTION OF ISCHEMIC BRAIN ACIDOSIS WITH A NOVEL THROMBOXANE RECEPTOR ANTAGONIST COMBINED WITH A THROMBOXANE SYNTHASE INHIBITOR
    PETTIGREW, LC
    HAZLE, JD
    GUTIERREZ, G
    ANNALS OF NEUROLOGY, 1990, 28 (02) : 223 - 224
  • [38] PHARMACOLOGICAL ACTIONS OF ICI-180080, A NOVEL THROMBOXANE RECEPTOR ANTAGONIST
    JESSUP, CL
    JESSUP, R
    WAYNE, M
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 1986, 38 (10) : 754 - 757
  • [39] CHARACTERIZATION OF BAY-U-3405, A NOVEL THROMBOXANE A2 ENDOPEROXIDE RECEPTOR ANTAGONIST
    PERZBORN, E
    FIEDLER, VB
    SEUTER, F
    STASCH, JP
    WEBER, H
    SANDER, E
    BOSHAGEN, H
    ROSENTRETER, U
    STROKE, 1990, 21 (12) : 143 - 145
  • [40] INHIBITION OF PLATELET ACTIVATION BY THE NOVEL THROMBOXANE RECEPTOR ANTAGONIST BM 13.505
    PATSCHEKE, H
    STEGMEIER, K
    HORNBERGER, W
    STAIGER, C
    NEUGEBAUER, G
    THROMBOSIS AND HAEMOSTASIS, 1987, 58 (01) : 182 - 182